Acta Med. 2008, 51: 101-105

https://doi.org/10.14712/18059694.2017.10

Ionizing Radiation Sensitizes Leukemic MOLT-4 Cells to TRAIL-induced Apoptosis

Martina Řezáčováa, Jiřina Vávrováb, Doris Vokurkovác

aCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Department of Medical Biochemistry, Hradec Králové, Czech Republic
bUniversity of Defense, Faculty of Military Health Sciences, Hradec Králové, Czech Republic
cCharles University in Prague, Faculty of Medicine and University Hospital Hradec Králové, Institute of Clinical Immunology and Allergology, Hradec Králové, Czech Republic

Received February 1, 2008
Accepted April 1, 2008

References

1. Belka C, Schmith B, Marini P, Durand E, Rudner J, Faltin HM, Bamberg M, Schutze-Osthoff K, Budach W. Sensitization of resistant lymphoma cells to irradiation/ induced apoptosis by the death ligand TRAIL. Oncogene 2001; 20:2190–6. <https://doi.org/10.1038/sj.onc.1204318>
2. Bucur O, Subrata R, Bucur MC, Almasan A. APO2 ligand-tumor necrosis factorrelated apoptosis-inducing ligand in prostate cancer therapy. Frontiers in Bioscience 2006; 11:1549–68. <https://doi.org/10.2741/1903>
3. Georgakis GV, Li Y, Humphreys R, Andreeff M, O Brien S, Younes M. Activity od selective fully human agonistic antibodies to the TRAIL death receptors TRAIL- R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction apoptosis and enhancement of doxorubicin – and bortezomib-induced cell death. Br J Haematol 2005; 130:501–10. <https://doi.org/10.1111/j.1365-2141.2005.05656.x>
4. Gong B, Almasan A. Apo2 ligand=TNF-related apoptosis-inducing ligand and death receptor 5 mediate the apoptotic signaling induced by ionizing radiation in leukemic cells. Cancer Res. 2000; 60:5754–60.
5. Henson ES, Johnston JB, Gibson SB. The role of TRAIL death receptors in the treatment of hematological malignancies. Leukemia and Lymphoma 2008; 49:27–35. <https://doi.org/10.1080/10428190701713655>
6. Ibrado AM, Huang Y, Fang G, Bhalla K. Over expression of Bcl-2 or Bcl-XL inhibits Ara-C-induced CPP32/Yama protease activity and apoptosis of human AML HL-60 cells. Cancer Res 1996; 56:4743–8.
7. Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia 2005; 19:2195–202. <https://doi.org/10.1038/sj.leu.2403946>
8. Kim K, Fisher MJ, Xu SQ, El-Deiry WS. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 2000; 6:335–46.
9. Meng RD, El-Deiry WS. p53 –indipendent upregulation of KILLER /DR5 TRAIL receptor expression by glucocorticoids and interferon-γ. Exp Cell Res 2001; 262: 154–69. <https://doi.org/10.1006/excr.2000.5073>
10. Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 2000; 407:810–16. <https://doi.org/10.1038/35037747>
11. Pan Q, Liu B, Liu J, Cai R, Wang Y, Qian C. Synergistic inductionof tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem 2007; 304:315–23. <https://doi.org/10.1007/s11010-007-9514-6>
12. Rich T, Allen RL, Wyllie AH. Defying death after DNA damage. Nature 2000; 407:777–82. <https://doi.org/10.1038/35037717>
13. Rezacova M, Vavrova J, Vokurkova D, Tichy A, Knizek J, Psutka J. The importance of abrogation of G2-phase arrest in combined effect of TRAIL and ioniying radiation. Acta Bioch Pol 2005; 52:889–95.
14. Safwat A. The role of low-dose total body irradiation in treatment of non- Hodgkin’s lymphoma: a new look at an old method. Radiother Oncol 2000; 56:1–8. <https://doi.org/10.1016/S0167-8140(00)00167-5>
15. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRAIL –induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818–21. <https://doi.org/10.1126/science.277.5327.818>
16. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003; 22:8628–33. <https://doi.org/10.1038/sj.onc.1207232>
17. Wen J, Ramadevi N, Nguyen D, Perkins C, Worthington E, Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000; 96:3900–6.
18. Yagita H, Takeda K, Hazakawa Y, Smith MJ, Okumura K. TRAIL and its receptor as targets for cancer therapy. Cancer Sci 2004; 95:777–83. <https://doi.org/10.1111/j.1349-7006.2004.tb02181.x> <PubMed>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive